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https://doi.org/10.1016/j.ccell.2018.03.006SUMMARYWe characterized the epigenetic landscape of genes encoding long noncoding RNAs (lncRNAs) across 6,475
tumors and 455 cancer cell lines. In stark contrast to the CpG island hypermethylation phenotype in cancer,
we observed a recurrent hypomethylation of 1,006 lncRNA genes in cancer, including EPIC1 (epigenetically-
induced lncRNA1). Overexpression of EPIC1 is associated with poor prognosis in luminal B breast cancer pa-
tients and enhances tumor growth in vitro and in vivo. Mechanistically, EPIC1 promotes cell-cycle progres-
sion by interacting with MYC through EPIC1’s 129–283 nt region. EPIC1 knockdown reduces the occupancy
of MYC to its target genes (e.g., CDKN1A, CCNA2, CDC20, and CDC45). MYC depletion abolishes EPIC1’s
regulation of MYC target and luminal breast cancer tumorigenesis in vitro and in vivo.INTRODUCTION
The most recent genome-wide characterization of the human
cancer transcriptome has demonstrated that lncRNA expression
is among the most pervasive transcriptional changes in cancer
(Du et al., 2013; Iyer et al., 2015). Further experimental evidence
indicates that lncRNAs can play important roles in tumorigenesis
(Du et al., 2016; Prensner and Chinnaiyan, 2011; Schmitt and
Chang, 2016; Zhu et al., 2016). Similar to protein-coding genes
(PCGs), lncRNA expression is subject to changes in gene dosage
(e.g., copy-number alterations) and promoter utilization (e.g.,
DNA methylation) that occur in cancer initiation and progression.
In this regard, lncRNA genes can be targeted by cancer somatic
alterations and thus play important roles in tumorigenesis. Recent
studies focusing on the identification of copy-number alterationsSignificance
Although global epigenetic alterations have been established a
lncRNA loci and their consequences in cancer development re
ization of epigenetic landscape of lncRNA genes in 20 cancer
rently epigenetically activated in tumors by hypomethylation
lncRNA genes with oncogenic activity. Using this strategy, we h
by interacting with the MYC protein and promoting cell-cycl
mechanisms of MYC activation in cancer and pave the way t
with EPIC1.
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This is an open access article under the CC BY-NC-ND license (http://(Hu et al., 2014; Leucci et al., 2016; Yan et al., 2015) and cancer
risk polymorphism in promoter regions (Guo et al., 2016) of
lncRNA genes have provided evidence demonstrating that so-
matic/germline alterations of lncRNA in tumors can be ‘‘driver
molecular events’’ leading to tumor initiation and progression.
Epigenetic regulation is one of the major mechanisms utilized
to control lncRNA expression and tissue specificity (Amin et al.,
2015; Guttman et al., 2009; Wu et al., 2010). Epigenetic
alterations have been established as one of the hallmarks of
tumorigenesis (Jones and Baylin, 2002; Shen and Laird, 2013).
However, the epigenetic alterations of lncRNA genes and their
consequences in cancer remain poorly characterized.
Genome-scale studies have yielded important insights into
DNA methylation changes in tumors (Irizarry et al., 2009; Noush-
mehr et al., 2010) but have mostly focused on PCG promoters.s a prominent cancer hallmark, the epigenetic abnormality of
main poorly characterized. We report an in-depth character-
types and discover that the expression of lncRNAs is recur-
. This study provides an integrative strategy of identifying
ave identified and validated EPIC1 as an oncogenic lncRNA
e progression. These discoveries expand upon the known
o develop therapies that target MYC through its interaction
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. LncRNA and PCGs Have Distinct
DNA Methylation Patterns in Ten Cancer
Types
(A) Weighted density plot (kde2d.weighted
[package: ggtern]) of differential DNA methylation
(indicated by FDR values) of 100 windows
within ±1,000 kb from transcription start sites
(TSSs) are shown in breast cancer tissues. The
windows are arranged based on their distances
to PCG TSS (x axis) and lncRNA gene TSS (y axis).
The promoter region is defined as ±3 kb (white
dashed lines) from TSS. The hypermethylation
region in tumor is shown as red, whereas the
hypomethylation region is shown as blue. The
average H3K27ac and H3K4me3 binding in-
tensities are shown along with the x and y axes.
(B) Differential DNA methylation between tumors
and matched normal tissues in nine cancer types.
(C) Distribution of the differential DNA methylation
weighteddensityvalues (kde2d.weighted [package:
ggtern]) within ±3 kb region (white dashed lines) of
PCG TSS (left) and lncRNA TSS (right) in ten cancer
types. NS, not significant.
See also Figure S1 and Table S1.The efforts to characterize the lncRNA epigenetic landscape in
cancers have labored under the limitations of an imperfect anno-
tation of lncRNAs and a dearth of platforms that can detect
lncRNA epigenetic and expression alterations in cancer. The
emergence of large-scale cancer genomic/epigenetic projects,
such as The Cancer Genome Atlas (TCGA) Research Network
project, have provided an excellent opportunity to characterize
the lncRNA epigenetic landscape in cancer.
Here, we repurposed and integrated multi-dimensional
genomic and epigenetic data from TCGA, Cancer Cell Line Ency-
clopedia (CCLE) (Barretina et al., 2012), and Catalog of Somatic
Mutations in Cancer (COSMIC) (Iorio et al., 2016) projects to
characterize the DNA methylation landscape of lncRNA genes
across 33 cancer types. We aimed to build a detailed knowledge
base and data analysis pipeline to explore DNA methylation
alterations of lncRNA promoters in cancer. We hypothesize that,
if some lncRNAgenesare recurrently targetedbyDNAmethylation
alterations in tumors, theymayplayan important role in tumor initi-
ationandprogression.By further integratingwith theTCGAclinical
data and somatic alterations of well-documented cancer genes,
we targeted to identify and mechanistically validate lncRNAs
that may have a tumor-promoting or tumor-suppressing function.
RESULTS
LncRNA Promoters Exhibit a Distinct Pattern of
Epigenetic Alterations in Cancer Compared with PCG
Promoters
To interrogate lncRNA DNAmethylation in cancer, we developed
a computational pipeline to repurpose HM450 probes to lncRNA
promoters (Figures S1A and S1B). This analysis resulted in aset of 225,868 probes annotated to
28,366 genes. Specifically, 66,832
HM450 probes were annotated to 9,606
lncRNA genes (29,117 CpG islands),comprising approximately 60.4% of all lncRNAs in ENCODE
annotation (Table S1). The lncRNAs that had at least one HM450
probe covering their promoters included 3,964 intergenic and
4,053 antisense lncRNA genes (Table S1). The median distances
between lncRNA promoters and their nearest HM450 probes is
1,267 bp. The identified DNA methylation probes are mainly
located within 3 kb regions of H3K4me3 and H3K27ac peaks of
their mapped genes (Figure 1A) (ENCODE Project Consortium,
2012), suggesting that the probes indeed represent the promoter
methylation status of lncRNAs and PCGs (Shlyueva et al., 2014).
We first sought to determine the lncRNA DNA methylation
pattern in cancer by comparing the DNA methylation profile of
lncRNA promoters between tumors and normal tissues using
the TCGA Pan-Cancer database (syn4382671, Table S1).
Because the CpG island hypermethylation phenotype (CIMP)
has been established as one of the hallmarks in many cancer
types (Baylin et al., 1986), we originally expected to identify
hypermethylated tumor-suppressing lncRNAs. Intriguingly, we
observed both hypermethylated and hypomethylated lncRNA
promoters in breast cancer tissues (Figures 1A and S1C). This
observation is in stark contrast to the PCG promoters, which
werepredominantlyhypermethylated inbreast cancer (Figure1A).
Of the intergenic lncRNAs that donot sharepromoterswithPCGs,
there were 504 intergenic lncRNA promoters showing significant
hypomethylation and 639 intergenic lncRNA promoters showing
significant hypermethylation in breast cancer (false discovery
rate [FDR] < 0.05 and effect size > 0.2). The hypomethylation
pattern of lncRNA promoters was consistently observed in
another nine cancer types that also had matched normal tissues
available (Figures 1B and S1D). To determine if this observation
was an artifact due to bias of the HM450 microarray design, weCancer Cell 33, 706–720, April 9, 2018 707
DA
EPIC1
MIR4666A
LINC00944
LINC00668
LINC00884
RP11−539E17.5
LINC00941
RP11−608O21.1
AK023033
CTD−3010D24.3
BC005081
LINC00460
MFI2−AS1
RP11−556E13.1
LOC102724297
SNHG12
BOLA2
MINCR
RP11−278L15.2
AC098973.2
AF186192.1
ZNF667−AS1
RP11−259O2.1
CTB−41I6.2
AK125737
LINC01197
HHIP−AS1
RP11−74E22.3
DPP10−AS1
CTD−2298J14.2
DIO3OS
RP3−412A9.16
LINC01158
BOLA3−AS1
FGF14−IT1
LOC100049716
SNHG18
HAND2−AS1
AC006026.13
CERS3−AS1
High reliability
ES lncRNAEA lncRNA
Intermediate
 reliability
High reliability
Intermediate
 reliability
BL
C
A
BR
C
A
C
ES
C
C
R
AD
G
BM
H
N
SC
KI
C
H
KI
R
C
KI
R
P
LA
M
L
LG
G
LI
H
C
LU
AD
LU
SC
PA
AD
PR
AD
SK
C
M
ST
AD
TH
C
A
U
C
EC
BL
C
A
BR
C
A
C
ES
C
C
O
AD
D
LB
C
ES
C
A
H
N
SC
KI
R
C
LC
LL
LG
G
LI
H
C
LU
SC
M
M
O
V
PA
AD
PR
AD
SA
R
C
SK
C
M
ST
AD
TH
C
A
Expressed Not expressed
ES lncRNAEA lncRNA
CB
AF186192.1 CTD−2298J14.2
DNA methylation beta value
R
el
at
iv
e 
ex
pr
es
si
onEPIC1
R
el
at
iv
e 
ex
pr
es
si
on
DNA methylation beta value
Normal Tumor Normal Tumor
RP11−539E17.5
0 0.5 1 0 0.5 1 0 0.5 1 0 0.5 1
10
10
10
3
2
10
10
2
10
10
10
3
2
10
10
2
r = -0.498 r = -0.645 r = -0.511 r = -0.233
(legend on next page)
708 Cancer Cell 33, 706–720, April 9, 2018
randomly permuted the labels of lncRNAs and PCGs for 10,000
times and generated an empirical distribution to estimate the
FDR for each promoter. This analysis revealed that the lncRNA
promoters were significantly hypomethylated in all ten cancer
types (p < 1015, Kolmogorov-Smirnov test, Figure 1C).
Integrative Analysis Identified 2,123 Recurrent
Epigenetically Regulated lncRNAs in 20 Cancer Types
To determine whether lncRNAs’ expression is regulated by the
DNAmethylation changes at their promoters (e.g., hypomethyla-
tion causes overexpression), we integrated the lncRNA expres-
sion data fromMiTranscriptome, which summarized the expres-
sion of 12,382 cancer-associated lncRNA transcripts using an ab
initio assembly method in 6,475 RNA sequencing (RNA-seq)
profiles, including 5,602 TCGA samples (Iyer et al., 2015). Our
analysis focused on TCGA samples across 20 cancer types
that have both DNA methylation and lncRNA expression data.
We applied a heuristic strategy to identify the lncRNAs that are
epigenetically activated (EA) or epigenetically silenced (ES) in
tumors in comparison to their DNA methylation status in normal
tissues. This method prioritized the lncRNAs that not only
exhibited a significant difference in DNA methylation between
tumors and normal tissues, but also exhibited expression
changes highly correlated with their DNA methylation alterations
(see details in the STAR Methods). A patient-centric matrix with
DNAmethylation status of 2,123 lncRNA genes across 20 cancer
types was characterized, including 1,006 EA and 1,117 ES
lncRNAs that showed epigenetic alteration in at least one cancer
type (Table S2). The top 20 most frequently EA and ES lncRNAs
are shown in Figure 2A. All the epigenetically regulated lncRNAs,
with either hypomethylation or hypermethylation in tumors, ex-
hibited a significant negative correlation (FDR < 0.01) between
their expression and promoter DNA methylation status (Figures
2B and 2C). Notably, a group of the EA lncRNAs in tumors was
not expressed in normal tissues (Figure S2A). This ‘‘on or off’’
expression pattern of EA lncRNAs potentiated them as prom-
ising diagnostic biomarkers. To further validate the methylation
status of the lncRNAs and their expression in cancer, we inves-
tigated the RNA-seq andHM450DNAmethylation profiles of 455
cancer cell lines from the CCLE and COSMIC databases (Barre-
tina et al., 2012). Among the top 40 lncRNAs, 34 (14 EA and 20 ES
lncRNAs) exhibited a similar expression pattern in cancer cell
lines and significantly negative correlation between their expres-
sion and promoter methylation (Figures 2D and S2B; Table S2).
Epigenetically Regulated lncRNAs Are Associated with
Tumor Survival and Protein-Coding Cancer Gene
Alterations
We next analyzed the association of lncRNA epigenetic status
with patient survival in 20 cancer types. Twelve of the topFigure 2. Epigenetic Landscape of lncRNAs in Cancer
(A) Percentages of significant EA (top panel) or ES (bottom panel) lncRNAs in 20 ca
alteration in each cancer type. Purple indicates EA lncRNAs; green indicates ES
(B and C) Correlation of representative EA (B) or ES (C) lncRNAs’ expression and t
y axis shows expression level based on RNA-seq; the x axis, DNA methylation b
(D) Expression of the top 20 EA (top panel) and ES (bottom panel) lncRNAs in canc
cell lines with the lncRNA expressed (purple, absolute read count > 0) or not exp
See also Figure S2 and Table S2.20 EA lncRNAs were significantly correlated with poor survival
in at least 1 cancer type, while 10 of the top 20 ES lncRNAs
were significantly correlated with favorable survival (Figures
S2C–S2E). Among these survival-related lncRNAs are SNHG12
and MINCR, which are epigenetically activated in multiple can-
cer types, including breast, bladder, endometrial, colorectal,
and lung cancer (Figure 2A; Table S2). These lncRNAs have
been documented to be overexpressed in a variety of cancer
types and to play oncogenic roles in regulating cell proliferation
and migration (Doose et al., 2015; Li et al., 2013; Ruan et al.,
2016). To explore the relationship between lncRNA epigenetic al-
terations and the somatic alterations of known tumor genes, we
integrated the lncRNA epigenetic alterations with the mutation
and copy-number alterations of known protein-coding cancer
genes in the same tumors (Vogelstein et al., 2013). Notably, the
epigenetically regulated lncRNAs show a strong co-occurrence
with a group of cancer gene mutations and copy-number alter-
ations (Figure S2F; Table S2). For example, EA lncRNAs are
significantly enriched in TP53mutated tumors in multiple cancer
types (Figures S2F and S2G). By contrast, ES lncRNAs exhibit
significant mutual exclusivity with EGFR amplifications and
mutations (Figure S2F).
EPIC1 Is Epigenetically Activated and Correlated with
Poor Survival in Breast Cancer
The lncRNA that is most frequently epigenetically activated in
multiple cancer types is ENSG00000224271 (epigenetically
induced lncRNA1 [EPIC1]) (Figure 2A). It is an intergenic lncRNA
(CPAT coding probability = 0.004) located on chr22:q13.31.
There are CpG islands within 164 bp downstream of this gene’s
transcription start site (Figure 3A). This lncRNA is epigenetically
activated in up to 90% of tumor samples across ten cancer
types, including breast cancer (Figures 2A and 2D; Table S2).
Our algorithm identified three probes in HM450 mapping to the
EPIC1CpG islands (Figure 3A). Based on the beta values of three
probes, three subgroups of breast cancer were identified by the
hierarchical clustering analysis in 534 breast tumors (Figure 3B).
The hypermethylated subgroup includes 196 (36.7%) breast tu-
mors and exhibits a high EPIC1methylation level similar to that in
normal breast tissues (Figure 3B). Breast tumors of this sub-
group are characterized by reduced EPIC1 expression (Figures
3C and 3D) and an improved overall survival in comparison to
the other two groups (Figure 3E). In contrast, patients whose tu-
mors exhibit EPIC1 hypomethylation and increased EPIC1
expression have the worst survival (Figures 3C–3E). To deter-
mine if EPIC1 expression is robustly associated with poor patient
survival in breast cancer, we re-annotated the probes from five
Affymetrix microarrays to lncRNAs and identified one probe
(1563009_at) in an Affymetrix HG-U133plus2 microarray that
specifically detected EPIC1 expression. As shown in Figure 3F,ncer types. Each pie chart indicates the percentage of each lncRNA epigenetic
lncRNAs.
heir DNAmethylation level in cancer tissues (red) and normal tissues (blue). The
eta values based on Infinium HM450 BeadChip.
er cell lines from the CCLE database. Each pie chart indicates the percentage of
ressed (green, absolute read count = 0) in each cancer type.
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increased expression of EPIC1was consistently associated with
poor survival in 6 independent patient cohorts, including 905
breast tumors (Figures 3F and S3A).
Further analysis revealed that EPIC1 epigenetic activation is
significantly associated with luminal B and HER2 subtypes of
breast cancer (p < 0.001, Figures S3B and S3C). In 119 TCGA
luminal B tumors, patients with EPIC1 epigenetic activation
demonstrated significant poor survival (p = 0.002, Figure S3D).
The association between EPIC1 and breast cancer poor survival
remains significant after adjusting cancer subtypes along with
other prognostic factors including age and clinical stage (multi-
variate Cox regression model p = 0.02). In all 20 cancer types
assessed, EPIC1 epigenetic activation is also significantly corre-
lated with poor survival in endometrial cancer patients (UCEC,
Figure S2C).
Using RNA-seq and HM450 DNA methylation data in the
CCLE database, we observed a significant negative correlation
(p < 0.05) between endogenous EPIC1 expression levels and its
promoter methylation in 24 breast cancer cell lines (Figures S3E
and S3F). Among them, 18 cell lines showed epigenetic activa-
tion of EPIC1, while 4 (i.e., MB231, HCC1937, CAMA1, and
ZR-75-30) exhibited promoter hypermethylation and had low
EPIC1 expression (Figures S3E and S3F). Decitabine treatment
caused a dosage- and time-dependent EPIC1 expression and
demethylation in EPIC1 hypermethylated cell lines (e.g.,
MB231), but not in cells that already exhibit EPIC1 hypomethy-
lation and overexpression (e.g., MCF-7) (Figures 3G, 3H, and
S3G). Using a similar strategy, we selected seven other EA
lncRNAs based on their novelty and demonstrated that decita-
bine treatment significantly induced EA lncRNAs expression by
decreasing the DNA methylation level of their CpG islands (Fig-
ure S3H; Table S2).
To determine if EPIC1 is directly regulated by DNA methyl-
ation, we cloned EPIC1’s promoter region (including the CpG
islands) and performed in vitroDNAmethylation assay (Figure 3I).
Luciferase reporter assays revealed that the unmethylated
EPIC1 promoter (unMeth-EPIC1) led to a significantly higher
reporter activity compared with the methylated version (Meth-
EPIC1) (p < 0.01, Figure 3I). Collectively, these results demon-
strated that EPIC1 is directly regulated by DNA methylation at
the CpG islands in its promoter region.Figure 3. Expression Level of EPIC1 Is Regulated by DNA Methylation
(A) The locations of EPIC1 gene (blue), CpG islands (green), and HM450 probes
(B) Heatmapwith beta values of DNAmethylation obtained from threeEPIC1HM45
using a hierarchical clustering analysis in tumors. Black, hypermethylation; green,
(blue) is shown as control. Full IDs of EPIC1 HM450 probes are cg10956848, cg
(C) Relative EPIC1 expression in three subgroups above, compared with the le
***p < 0.001.
(D) Correlation of EPIC1 expression with EPIC1 DNAmethylation status in breast c
status.
(E) Kaplan-Meier survival curve represents the proportion survival of breast canc
(F) Forest plot of EPIC1’s association with survival in six independent breast can
U133_Plus_2).
(G) qRT-PCR analysis of EPIC1 expression in MCF-7 and MB231 cells treated w
(H) EPIC1 methylation status detected by the same three probes (B) in breast ca
value are shown.
(I) Reporter assay of methylated and unmethylated EPIC1 promoters (top). In vitro
enzyme (bottom).
Error bars indicate mean ± SD, n = 3 for technical replicates. **p < 0.01. NS, not
See also Figure S3.EPIC1 Functions as a Potential Oncogenic lncRNA by
Promoting Cell-Cycle Progression
To evaluate the oncogenic role of EPIC1 in cancer, we analyzed
the EPIC1 expression status in 28 cell lines across 8 cancer
types using qRT-PCR. In agreement with EPIC1’s activation in
the luminal B breast cancer subtype, EPIC1 is overexpressed
in luminal breast cancer cell lines (e.g., BT-474, MB361,
MCF-7, ZR-75-1, and T-47D) (Lehmann et al., 2011), along
with ovarian cancer (A2780cis andOVCAR-4), pancreatic cancer
(BxPC-3 and PANC-1), prostate cancer (PC-3), and leukemia
(K562) cell lines (Figures S4A–S4C). We further performed
50-RACE and 30-RACE cloning using total RNA from MCF-7
and T-47D cells to identify functional EPIC1 isoforms. Three
splice variants of EPIC1 were cloned, including isoform v1
(567 nt), isoform v2 (844 nt), and isoform v3 (882 nt) (Figures
S4D–S4F). All of them share same exon 1 and exon 2. We
designed six siRNAs targeting shared sequence of all isoforms
and screened three siRNAs that can readily knockdown EPIC1
expression (Figure S4G). EPIC1 knockdown resulted in a
decrease of cell proliferation in a time-dependent manner in
luminal breast cancer cells MCF-7 and ZR-75-1 (Figures
4A–4F). Soft agar assays further demonstrated that EPIC1
knockdown significantly inhibits the anchorage-independent
growth of cancer cells (Figure 4G). Moreover, cell-cycle analysis
revealed that silencing of EPIC1 resulted in G0/G1 arrest in
MCF-7 and ZR-75-1 cells (Figures 4C, 4F, and S4H). Next, we
established stable EPIC1 knockdown cells using lentiviral
shRNAs. Both shEPIC1 stable cells exhibited significantly
reduced cell proliferation (Figures S4I and S4J), anchorage-inde-
pendent growth (Figure S4K), and in vivo xenograft growth (Fig-
ures 4H and 4I), compared with the shCtrl cells. These results not
only suggest oncogenic activity of EPIC1 in vivo, but also provide
a potential therapeutic target for breast cancer treatment.
EPIC1 Is a Nuclear lncRNA that Regulates MYC Targets
Cell fractionation PCR and subcellular RNA-seq analyses re-
vealed that EPIC1 RNA is predominately located in the nucleus
(Figures 5A, S5A, and S5B), suggesting that EPIC1 might play
a role in transcriptional regulation and chromatin interactions
(Batista and Chang, 2013). To explore this possibility, RNA-seq
analyses were performed on MCF-7 cells transfected with twoand Associated with Poor Survival in Breast Cancer Patients
(red) in GRCh37 reference human genome (chr22:48,027,423-48,251,349).
0 probes in breast normal tissues and tumors. Three subgroupswere identified
intermediate; red, hypomethylation. EPIC1’s DNAmethylation in normal tissues
14752348, and cg08040429.
vel in normal tissues, respectively. The error bars represent standard errors.
ancer and normal tissues. Probe cg08040429 represents the DNAmethylation
er patients with three subgroups above.
cer cohorts. EPIC1’s expression is measured by Affymetrix 1563009_at (HG-
ith decitabine (DAC).
ncer cell lines treated with decitabine. Differences in z score-transformed beta
DNAmethylation status of EPIC1 promoters was confirmed by Hpall restriction
significant.
Cancer Cell 33, 706–720, April 9, 2018 711
siCtrl
ZR-75-1
siE1 siE2siCtrl siE1 siE2
MCF-7G
shCtrl
shE1
shE2
IH
A
D E
B C
F
0
2
4
6
8 siCtrl
siE1
siE2
R
el
at
iv
e 
gr
ow
th
 ra
te
0 1 2 3 4
Day(s)
**
**
**
**
P
er
ce
nt
ag
e 
of
 c
el
ls100
80
60
40
20
0
G0/G1 S G2/M
**
** **
siCtrl
siE1
siE2
**
* ** *P
er
ce
nt
ag
e 
of
 c
el
ls100
80
60
40
20
0
G0/G1 S G2/M
siCtrl
siE1
siE2
0
0.5
1.0
1.5
R
el
at
iv
e 
E
P
IC
1 
le
ve
l
siC
trl
siE
1
siE
2
**
**
0
0.5
1.0
1.5
R
el
at
iv
e 
E
P
IC
1 
le
ve
l
** *
siC
trl
siE
1
siE
2
15
0
** **
R
el
at
iv
e 
# 
of
 c
ol
on
ie
s
10
0
50
0
siC
trl
siE
1
siE
2
15
0
** **
R
el
at
iv
e 
# 
of
 c
ol
on
ie
s
10
0
50
0
siC
trl
siE
1
siE
2
** **0.00
0.05
0.10
0.15
Tu
m
or
 w
ei
gh
t (
g)
sh
Ct
rl
sh
E1
sh
E2
0 1 2 3 4
0
2
4
6 siCtrl
siE1
siE2
R
el
at
iv
e 
gr
ow
th
 ra
te
Day(s)
**
**
**
**
0 21 3 4 5 6 7 8
200
100
150
50
0
Tu
m
or
 v
ol
um
e 
(m
m
3)
Week(s)
shCtrl
shE1
shE2
Figure 4. EPIC1 Functions as an Oncogenic lncRNA in Breast Cancer
(A–C) qRT-PCR analysis of EPIC1 (A), MTT assay (B), and cell-cycle analysis (C) in MCF-7 cells treated with EPIC1 siRNAs (siE1 and siE2).
(D–F) qRT-PCR analysis of EPIC1 (D), MTT assay (E), and cell-cycle analysis (F) in ZR-75-1 cells treated with EPIC1 siRNAs.
(G) Anchorage-independent colony formation assays of MCF-7 (left) and ZR-75-1 (right) cells treated with EPIC1 siRNAs.
(H) Quantification of tumor growth in xenograft mouse models bearing with stable EPIC1 knockdown (shE1 and shE2) or control (shCtrl) MCF-7 cells.
Error bars indicate means ± SD, n = 3 for technical replicates. *p < 0.05, **p < 0.01.
(I) Representative tumor size (left), and quantification of tumor weight (right) from xenograft mousemodels. Data are presented asmeans ± SD (n = 10). **p < 0.01.
See also Figure S4.siRNAs targeting EPIC1 individually or pooled. We have
confirmed that both siRNAs can readily knockdown the level of
nuclear EPIC1 RNA (Figure S5C). To exclude possible off-target
effects on gene expression associated with single siRNAs, we
focused only on genes regulated in the same direction in all three
transfection experiments. EPIC1 knockdown in MCF-7 cells re-
sulted in the regulation of 805 genes (upregulation of 317 genes
and downregulation of 488 genes) (Figure 5B; Table S3), which712 Cancer Cell 33, 706–720, April 9, 2018are highly overlapped with 2,005 EPIC1-associated genes that
were significantly correlated with EPIC1 expression across 559
TCGA breast tumors (p = 2.6 3 1025, Figures 5B and 5C).
This overlap was even higher in the pathway analysis. Gene
set enrichment analysis (GSEA) analysis showed that cell-cy-
cle-related biological processes such as ‘‘MYC targets,’’ ‘‘G2M
checkpoint,’’ and ‘‘E2F targets’’ were significantly enriched in
the EPIC1-associated genes in 17 out of 20 cancer types
1740 540265
EPIC1-correlated
genes in tumor samples 
EPIC1-regulated
genes in cell lines 
p = 2.6 x 10-25
EPIC1 expression
+
Protein coding
 gene expression
EPIC1 siRNA
+
RNA-seq
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(Figure 5D; Table S3). The same cellular processes were
enriched in theEPIC1-regulated genes inMCF-7 cells (Figure 5D;
Table S3). Among them, the MYC pathway/targets are promi-
nent gene sets enriched with EPIC1-regulated genes in both
tumor samples and cell lines (Figure 5E). For example, the
MYC targets CDC45, CDC20, and CCNA2 were significantly
downregulated by EPIC1 knockdown. Moreover, CDKN1A (en-
coding the p21 protein) was significantly induced after EPIC1
knockdown (Figures 5F, 5G, and S5D). p21 is a well-established
negative regulator of cell-cycle progression at G1 and S phase
that is directly inhibited by MYC (Gartel and Radhakrishnan,
2005). These observations are consistent with our observation
that EPIC1 knockdown resulted in cancer cells’ arrest at G0/G1
phase. Similarly, in MCF-7 and ZR-75-1 cells, MYC knockdown
also led to a pattern of MYC target expression and cell growth
comparable with EPIC1 knockdown (Figures 5G and S5E–
S5H). This suggested that the oncogenic role of EPIC1 may be
associated with MYC protein.
EPIC1 Interacts with the 148–220 Amino Acid Region of
MYC through Its 129–283 nt Sequence
To study the interaction between EPIC1 RNA and MYC protein,
we overexpressed each of three EPIC1 isoforms (i.e., v1, v2, and
v3) with Flag-tagged MYC protein in 293T cells, and performed
RNA immunoprecipitation (RIP) assay. This analysis revealed
that EPIC1 isoforms v1 and v2 could be enriched by MYC RIP
(Figure S6A). In v1 or v2 isoforms overexpressing MCF-7 cells,
only the v1 isoform could regulate MYC target genes (Figures
S6B and S6C). We further observed that overexpression of the
EPIC1 v1 isoform promoted G1 phase progression and in vivo
xenograft growth (Figures S6D–S6F). It is apparent to us that
the v1 isoform is the functional isoform of EPIC1 gene in breast
cancer. We therefore used isoform v1 (567 nt) as the reference
sequence of EPIC1 in the following study.
RNA pull-down assay showed that MYC protein could be
co-precipitated by an in-vitro-transcribed biotinylated EPIC1
sense transcript, but not by the EPIC1 antisense transcript (Fig-
ure 6A). MYC RIP with cell lysates from MCF-7 cells was then
performed to confirm the interaction between endogenous
EPIC1 and MYC protein (Figures 6B, S6G, and S6H). A well-
documented MYC interacting lncRNA, PVT1 (Tseng et al.,
2014), was included as positive control and could also be
enriched by MYC RIP (Figure 6B). Further in vitro binding assay
using in-vitro-transcribed EPIC1 RNA and recombinant His-
tagged MYC protein demonstrated that EPIC1 binds directly toFigure 5. EPIC1 Is a Nuclear lncRNA Regulating MYC Targets Express
(A) qRT-PCR analysis of EPIC1 expression (top) and western blot (bottom) of subc
cytoplasmic and nuclear gene localization, respectively. SNRP70 and GAPDH se
cytoplasmic (Cyto), and nuclear fractionation (Nuc). Error bars indicate mean ± S
(B) Schematic of the identification of EPIC1 correlated genes in breast tumor
cells (green).
(C) Co-expression analysis showing that EPIC1 expression is associated with 2,0
one patient.
(D) Gene set enrichment analysis (GSEA) of the EPIC1-related pathways in 20 c
heatmap indicates the GSEA scores.
(E) Association between the enrichment of MYC targets and EPIC1 expression in
(F) EPIC1-regulated gene expression by qRT-PCR analysis (top) and RNA-seq (b
(G) Western blot of MYC-regulated targets in MCF-7 (left) and ZR-75-1 (right) ce
See also Figure S5 and Table S3.
714 Cancer Cell 33, 706–720, April 9, 2018MYC protein (Figure 6C). To map the EPIC1 functional motifs
corresponding to MYC binding, we conducted an in vitro RNA
pull-down assay using a series of truncated EPIC1 fragments.
This analysis revealed that nucleotides 1–358 of EPIC1 (EPIC1
1–358 nt) are sufficient to interact with MYC protein, while other
EPIC1 truncated fragments could not (Figure 6D). To map with
greater precision the sequence of EPIC1 that binds to MYC,
we further designed seven truncated or deletion mutants of the
EPIC1 1–358 nt region and revealed that three deletion mutants
(D121-180 nt, D181-240 nt, and D241-300 nt) can abolish EPIC1
binding to MYC protein. Deletion of all three regions (129–283 nt)
also abolished EPIC1’s interaction with MYC protein (named as
DMYC-EPIC1; Figures 6E and 6F). These data suggested that
the EPIC1 129–283 nt region is necessary for EPIC10s binding
to the MYC protein. MYC protein domain mapping studies re-
vealed that EPIC1 binds the 148–220 amino acid (aa) region of
MYC, which is not overlapped with the well-characterized tran-
scriptional activation domain and basic-helix-loop-helix domain
of MYC protein (Luscher, 2001; von der Lehr et al., 2003) (Figures
6G and 6H). Deletion of the 148–220 aa region of MYC protein
(named as DEPIC1-MYC) abolished its interaction with EPIC1
(Figures 6G and 6H). Collectively, our findings demonstrated
that EPIC1 interacts with the 148–220 aa region of MYC through
its 129–283 nt sequence.
The Oncogenic Role of EPIC1 Partially Depends on Its
Regulation of MYC Occupancy on Target Promoters
With the observation that EPIC1 directly interacts with MYC, we
further analyzed the effect of EPIC1 on MYC target gene
reporters (e.g., p21 and CCNA2 promoters) in MCF-7 cells.
The reporter assays revealed that knockdown of either EPIC1
orMYC significantly regulates p21-Luc and CCNA2-Luc reporter
luciferase activities (Figure 7A). These observations indicate that
EPIC1 directly regulates the expression of MYC targets through
their promoter regions. Interestingly, EPIC1 knockdown had little
effect on the expression of MYC (Figure 5G), which led to our
hypothesis that EPIC1 may regulate the transcriptional activity
of the MYC protein.
To test this hypothesis, we performed an integrated analysis on
MYC chromatin immunoprecipitation sequencing (ChIP-seq)
data (Lee et al., 2012) and RNA-seq data of EPIC1 knockdown
MCF-7 cells. Among 805 EPIC1-regulated genes, 785 have
robust MYC occupancy on their promoters in two biological
replicates of MCF-7 ChIP-seq data. Interestingly, we did not
observe a significant correlation between global MYC bindingion
ellular fractionation in MCF-7cells.GAPDH and U6 RNA served as markers for
rved as a specific nuclear and cytoplasmic marker to whole-cell lysates (WCL),
D, n = 3 for technical replicates.
s from TCGA (yellow), and genes potentially regulated by EPIC1 in MCF-7
05 genes in 559 patients with breast cancer (BRCA). Each column represents
ancer types (left panel) and EPIC1 knockdown MCF-7 cells (right panel). The
breast tumors by GSEA analysis (D).
ottom). Error bars indicate mean ± SD, n = 3 for technical replicates.
lls treated with EPIC1 and MYC siRNAs.
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Figure 6. EPIC1 Binds Directly with MYC
(A) Western blot of MYC proteins retrieved by in-vitro-transcribed biotinylated EPIC1 from MCF-7 cell nuclear extracts. Antisense EPIC1 was used as a negative
control. S, sense strand; AS, antisense strand.
(B) qRT-PCR analysis ofEPIC1 andPVT1 enriched byMYCproteins inMCF-7 cells.Western blot ofMYC is shown (right).HOTAIR andGAPDH served as negative
controls. Error bars indicate mean ± SD, n = 3 for technical replicates. **p < 0.01.
(C) Western blot of recombinant MYC proteins retrieved by EPIC1 RNA in in vitro binding assay. EPIC1 antisense was used as a negative control.
(D) Western blot of MYC pulled down by truncated EPIC1.
(E) Mapping of the MYC binding region within the 1–358 region of EPIC1.
(F) Schematic of truncated or deletion mutants of EPIC1. The MYC binding capability is shown (right).
(G) Western blot of truncated MYC proteins retrieved by in-vitro-transcribed EPIC1.
(H) Schematic of truncated MYC protein. The EPIC1 binding capability is shown. TAD, N-terminal transactivation domain; MB1-3, MYC boxes 1–3; bHLHLZ,
basic-helix-loop-helix-leucine zipper domain; CTD, C-terminal domain.
See also Figure S6.affinity and differential expression (i.e., fold change) after EPIC1
knockdown in MCF-7 cells, suggesting that EPIC1 may regulate
MYC’s occupancy on a specific group of targets. By further
considering previously validated MYC targets (Li et al., 2003;
Zeller et al., 2006), we identified 40 possible targets of the
EPIC1-MYC regulatory axis (Figures 7B and S7A; Table S4).
ChIP-qPCR were performed and validated that EPIC1 knock-
down significantly reducesMYC’s occupancies on the promotersof 26 targets, including CDKN1A (p21), CCNA2, CDC20, and
CDC45 (Figures 7C, S7B, and S7C). It is known that MYC binds
to DNA and functions as a transcription factor by heterodimeriza-
tion with another transcription factor, MAX (Amati et al., 1993;
Blackwood and Eisenman, 1991). MYC and MAX Co-IP assay
inMCF-7 cells revealed that EPIC1 knockdown could moderately
reduce the formation of MYC-MAX complexes (Figure S7D).
Moreover, overexpression of EPIC1, but notDMYC-EPIC1, couldCancer Cell 33, 706–720, April 9, 2018 715
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Figure 7. MYC Is Required for the Regulatory Role of EPIC1 in Cancer
(A) Reporter assay of CDKN1A (p21) and CCNA2 (Cyclin A2) promoters.
(B) Alignment of two biological replicates of MYC ChIP-seq in MCF-7 cells (green) and RNA-seq from siCtrl (blue) and siEPIC1 (red) RNA-treated MCF-7 cells.
CDKN1A and CCNA2 genomic locus are shown.
(C) ChIP-qPCR analysis of MYC occupancy on the promoters of target genes in MCF-7 cells treated with EPIC1 siRNAs.
(DandE)Western blot ofMYC targets (D) andMTTassay (E) after treatmentwithMYC siRNAs inMCF-7cellswith stable overexpression ofEPIC1andempty vector.
(F and G) Cell-cycle analysis (F) and qRT-PCR analysis of EPIC1, CDKN1A, and CCNA2 level (G) in MCF-7 cells transfected with LNA against EPIC1 followed by
overexpression of indicated vectors.
Error bars indicate mean ± SD, n = 3 for technical replicates. *p < 0.05, **p < 0.01. NS, not significant.
See also Figure S7 and Table S4.
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enhance the reporter luciferase activities mediated by MYC
and MAX (Figure S7E). These results suggest that EPIC1 pro-
motes MYC’s occupancy on EPIC1-regulated genes through its
129–283 nt sequence (i.e., MYC-binding sequence).
To further determine the role of the EPIC1-MYC regulatory axis
in cancer, we performed the MYC knockdown in EPIC1 stably
overexpressing MCF-7 cells, and observed that EPIC1 regula-
tion of cell proliferation and MYC target expression were attenu-
ated byMYCknockdown (Figures 7D and 7E). Overexpression of
MYC, but not EPIC1-binding-deficient mutant MYC proteins
(DEPIC1-MYC), regulates CCNA2 and p21 expression (Fig-
ure S7F). We further depleted the endogenous EPIC1 expression
using locked nucleic acid (LNA) in MCF-7 cells, followed by
overexpression of either LNA-resistant wild-type EPIC1 (WT-
R-EPIC1) or deletion mutant of 129–283 nt MYC binding region
(DMYC-R-EPIC1). Similar to EPIC1 siRNA treatment, LNA
knockdown of EPIC1 significantly caused G1 arrest of MCF-7
cells, which could be rescued by reintroduction of full-length
EPIC1, but not DMYC-EPIC1 (Figures 7F and S7G). The expres-
sion of full-length and the truncated EPIC1swas confirmed to be
comparable levels to rule out the influence of transfection effi-
ciency (Figure 7G). Consistently, LNA knockdown of EPIC1
also curtailed the expression of MYC target genes. Reintroduc-
tion of wild-type EPIC1, but not DMYC-EPIC1, was able to
rescue the regulation of these genes (Figure 7G). These results
suggested that the oncogenic role of EPIC1 is at least in part
dependent on its interaction with the MYC protein.
DISCUSSION
Previous studies, by repurposingcopy-number andgeneexpres-
sionmicroarray data, have successfully identified the copy-num-
ber alterations (Hu et al., 2014; Leucci et al., 2016; Tseng et al.,
2014; Yan et al., 2015) and expression alterations of lncRNA
(Du et al., 2013) in cancer. In the present study, we repurposed
and integrated multi-dimensional genomic and epigenetic data
from 6,475 tumor samples and 455 cancer cell lines in the
TCGA and CCLE projects. These data were remapped/realigned
to 9,606 annotated human lncRNAs to comprehensively charac-
terize the lncRNA DNA methylation landscape in cancer. Our
analyses demonstrate that integrating HM450 microarray and
RNA-seq data is a cost-effective strategy to research the DNA
methylation regulation of lncRNA genes given the large number
of HM450 and RNA-seq datasets available in public repositories.
Our study has revealed that lncRNAs can be epigenetically acti-
vated in tumors by loss of DNA methylation in the promoter re-
gion, which is in stark contrast to the well-documented CIMP
phenotype of PCGs in tumors. By further integrating with the pro-
tein-coding cancer gene alterations in same tumors, we
observed that lncRNA epigenetic activation exhibited a strong
co-occurrence with TP53 mutation in multiple cancer types.
Emerging evidence has demonstrated that p53 is a master regu-
lator of lncRNAs’ expression in cancer (Sanchez et al., 2014;
Schmitt et al., 2016). Future study is warranted to determine
whether loss of DNA methylation makes the promoters of these
lncRNAs accessible to transcription factors, such as p53, and
leads to transcriptional activation.
We hypothesize that, if some lncRNAs are recurrently targeted
by epigenetic alterations in tumors, they may play an importantrole in tumor initiation and progression. Indeed, the epigeneti-
cally regulated lncRNAs identified in this study include a number
of known cancer-related lncRNAs, such as KCNQ1OT1 (Engel
et al., 2000), MEG3 (Zhou et al., 2012), MINCR (Li et al., 2013),
HOTAIR (Gupta et al., 2010), and WT1-AS (Hancock et al.,
2007). Consistent with their somatic DNAmethylation alterations
identified in this study, germline epigenetic defects in some of
those lncRNAs have been documented to cause predisposition
to Wilms tumor (Scott et al., 2008) and pediatric adrenocortical
tumors (Wijnen et al., 2012).
Encouraged by the recapitulation of documented cancer-
related lncRNAs, we mechanistically validated the most
frequently EA lncRNA, EPIC1, as a potential oncogene. We
have demonstrated that EPIC1 interacts with MYC protein
through its 129–283 nt region and increases MYC occupancy
on EPIC1-regulated genes. The oncogenic role of MYC has
been well documented in cancer initiation and progression
(Dang, 2012). As an oncogene,MYC can be activated bymultiple
mechanisms in cancer. Chromosomal rearrangement is believed
to be the most common genetic alteration ofMYC (Dang, 2012).
Other MYC activation mechanisms include transcriptional regu-
lation, mRNA stabilization, and protein overexpression and
stabilization (Kress et al., 2015). Emerging evidence has uncov-
ered lncRNA’s role for MYC activation in cancers. Three recent
reports identified lncRNA CCAT1-L (colorectal cancer-associ-
ated transcript 1), GHET1 (gastric carcinoma highly expressed
transcript 1), and PCGM1 (prostate cancer gene expression
marker 1) to be involved in modulating the transcription (Xiang
et al., 2014) or RNA stability (Yang et al., 2014) of MYC in colo-
rectal, gastric, and prostate cancers (Hung et al., 2014). Another
study demonstrated lncRNA PVT1 (plasmacytoma variant trans-
location 1) as an oncogenic lncRNA that interacts and stabilizes
the MYC protein (Tseng et al., 2014).
However, little is known about whether and how lncRNAs
regulate the transcriptional activity of MYC. MYC protein alone
cannot form a homodimer nor bind to DNA in vivo. In most
cases, MYC heterodimerizes with a partner protein, MAX
(Amati et al., 1993; Blackwood and Eisenman, 1991) via a
basic-helix-loop-helix-leucine zipper domain. The MYC-MAX
complex binds directly to DNA sequence (CACA/GTG), which
is a subset of the general E-box (CACGTG) DNA recognition
sequence and functions as transcriptional activator or
repressor (Blackwood and Eisenman, 1991; Luscher, 2001). It
has been reported that MYC is bound to 25,000 sites in the
human genome (Cawley et al., 2004; Fernandez et al., 2003).
Among those in vivo MYC binding sites, only a small set of
sites have an MYC-MAX consensus CACA/GTG sequence
(Fernandez et al., 2003). One reason for this discrepancy is
that MYC can be recruited to non-canonical binding sites by
other transcription factors. For example, MYC can interact
with Miz1, which recruits MYC to its core promoter sequences
that lack an MYC-MAX binding motif (Peukert et al., 1997).
Other proteins, which recruit MYC to their cognate DNA bind-
ing sites, include specificity protein-1 (Gartel et al., 2001), nu-
clear factor Y (Izumi et al., 2001), transcription factor II-I) (Roy
et al., 1993), and yingyang-1 (Shrivastava et al., 1993). In the
current study, our results suggest that EPIC1 specifically
regulates MYC’s occupancy on a subset of MYC targets.
Our results also showed that EPIC1 can moderately enhanceCancer Cell 33, 706–720, April 9, 2018 717
MYC-MAX interaction. It is possible that EPIC1 only influences
MYC’s occupancy on canonical MYC-MAX binding sites, but
not the non-canonical MYC binding sites mediated by other
‘‘tethering factors.’’ Another possible explanation is that
EPIC1 may function as a ‘‘guide’’ RNA to facilitate MYC-
MAX’s regulation on specific targets by directly binding to
double-strand DNA. Future study is required to further define
how EPIC1 regulates MYC’s occupancy on these specific
MYC targets.
In summary, the establishment of a detailed knowledge base
of the DNA methylation-altered lncRNAs in cancer will facilitate
the identification of cancer-driving lncRNAs. Moreover, the
mechanistic characterization of EPIC1 and its functional cross-
talk with the well-established oncogene MYC may help to pave
the way to develop cancer therapies that target MYC through
its interaction with EPIC1. The strong prognostic association of
EPIC1, the robust tumor growth suppression by the EPIC1
knockdown, and the illustration of EPIC1’s mechanism to pro-
mote breast cancer will shed light on the future development
of lncRNA-based breast cancer therapies.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture, RNA Interference, LNA Transfection, and Plasmid Transfection
Human breast epithelial cell line, MCF10A, and human breast cancer cell lines, BT-20, BT-474, HCC1937, Hs578T, MCF-7, MDA-
MB-231 (MB231), MDA-MB-361 (MB361), MDA-MB-468 (MB468), T-47D, and ZR-75-1, and human ovarian cancer cell lines,
SK-OV-3, and NIH: OVCAR-3, and human pancreatic cancer cell lines, AsPC-1, BxPC-3, and PANC-1, and human prostate cancer
cell lines, DU 145, and PC-3, and human leukemia cell line K562, and human lung cancer cell line A549, and human cervical cancer
cell line HeLa, and human liver cancer cell line Hep G2, and human embryonic kidney (HEK) 293T cells were purchased from Amer-
ican Type Culture Collection (ATCC) and cultured as suggested by ATCC’s guidelines. Human ovarian cancer cell lines, IGR-OV-1,
OVCAR-4, and OVCAR-8 were purchased fromNIH/NCI and kept in RPMI 1640medium supplemented with 10% fetal bovine serum
(FBS), 1% penicillin, and 1% streptomycin. The A2780 human ovarian cancer cell line and the cisplatin resistant version of the cell
line, A2780cis, were obtained from the European Collection of Cell Cultures (ECACC), supplied by Sigma-Aldrich, and cultured in
RPMI 1640 medium supplemented with 2 mM glutamine, 10% FBS, 1% penicillin, and 1% streptomycin; A2780cis cells were
also supplemented with 1 mM cisplatin. Human pancreatic duct epithelial cell line (HPDE), and phoenix cells were kindly provided
by Dr. Wen Xie (Department of Pharmaceutical Sciences, University of Pittsburgh), and HPDE cells were maintained in Keratino-
cyte-SFM medium supplemented with human recombinant epidermal growth factor and bovine pituitary extract (ThermoFisher,
#17005042) and phoenix cells were maintained in DMEM supplemented with 10% FBS, 1% penicillin, and 1% streptomycin.
For RNA interference, cells were transfected with 40 nM siRNA targeting EPIC1, MYC, or a control siRNA using Lipofectamine
RNAiMAX (ThermoFisher, #13778150) per the manufacturer’s instructions. Total RNA was isolated 72 hr later for real-time PCR
analysis. The siRNA sequences are listed in Table S5.
For LNA transfection, cells were transfected with 40 nMLNA oligos targeting EPIC1, and a scramble control using LipofectamineTM
RNAiMAX per the guidelines. The LNA oligos were designed and synthesized from Exiqon, and detailed sequences are listed in
Table S5.
For plasmid transfection, cells were transfected with plasmid using LipofectamineTM 2000 (ThermoFisher, #11668019) or Lipofec-
tamineTM 3000 (ThermoFisher, #L3000015) as suggested approaches.e4 Cancer Cell 33, 706–720.e1–e9, April 9, 2018
In Vivo Xenograft Model
Briefly, 5- to 6-week-old female athymic nudemice (Charles River) were used for the xenograft model. MCF-7 cells stably expressing
shCtrl and shEPIC1were trypsinized and washed twice with sterilized PBS, and then, 0.2 ml of PBS containing 5 x 106 cells was sub-
cutaneously inoculated into the flanks of the mice. Mice were monitored twice every week for tumor growth, and tumor size was
measured using a caliper. Tumor volume in mm3 was calculated using the formula: Tumor volume = 0.5 x (width)2 3 length. Eight
weeks after inoculation, micewere sacrificed in keepingwith the policy for the humane treatment of tumor-bearing animals. All animal
studies were performed in accordance with the institutional guidelines, and the experiments followed the protocols approved by the
Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh.
METHODS DETAILS
Data Collection
DNA methylation, PCG expression, whole-exome mutation and GISTIC copy number alteration data were downloaded from TCGA
Pan-Cancer project (Data Freeze 1.3). The lncRNA annotation was downloaded from GENCODE (V22, GRCh38). There were 7,656
intergenic, 5,565 antisense, and 920 sense intronic lncRNAs. H3K4me3 and H3K27ac ChIP-seq data for seven cell lines were down-
loaded from the UCSC genome browser: Integrated Regulation from ENCODE Tracks. DNA methylation data for breast cancer cell
lines were downloaded from GSE57342 (Li et al., 2014) and GSE44837 (Di Cello et al., 2013).
RNA-seq data from 781 cancer cell lines in the CCLE database were downloaded from Expression Atlas (E-MTAB-2770). HM450
DNA methylation profile of 1,028 cancer cells lines form COSMIC database (Iorio et al., 2016). There are 455 cells which have both
HM450 DNAmethylation and RNA-seq data. The BAM files of RNA-seq of 939 breast cancer tumors were downloaded from Cancer
Genomics Hub.
Mapping the Probes to GENCODE Genes
The genomic coordinates of HM450 probes based on GRCh37 were first transferred to genomic coordinates in GRCh38 using
LiftOver (UCSC genome browser). We then searched the nearest TSS of PCG and lncRNA for each probe based on GENCODE
V22 annotation. In this way, we defined: (1) the PCG probes, located in the PCG promoter region (+/- 3 kb from the TSS); (2) the
lncRNA probes, located in the lncRNA promoter region; (3) the shared probes, located in both the PCGand lncRNA promoter regions;
and (4) the non-probes, which are not located in any promoter regions (Figure S1B).
DNA Methylation Dysregulation Pattern Analysis in Cancers
DNA methylation dysregulation in cancers showed a different beta value pattern in lncRNA promoter and protein-coding promoter
regions. To evaluate the statistical significance of the difference between methylation in lncRNA and PCG promoter regions, we
permuted the annotation for each probe 10,000 times to generate an experimental distribution of DNA methylation change. Through
comparison with the experimental distribution, an empirical p value could be calculated. Finally, the weighted two-dimensional kernel
density estimation R function kde2d.weighted (package: ggtern) was used to measure the distribution of hypomethylation or hyper-
methylation according to the distance to promoters of lncRNA and PCGs.
MiTranscriptome Data Renormalization
Recent reports have revealed that highly expressed genes affect the normalization scale much more and cause a bias against low-
expression genes such as lncRNAs (Li et al., 2010a; Wagner et al., 2012). To precisely evaluate the alteration of lncRNA expression in
tumors, we renormalized the MiTranscriptome profile using a method similar to that described in S. Anders et al. (Anders and Huber,
2010). Specifically, a scaling factor for each sample was calculated as the median of the expression ratio to a pseudo-reference
sample for each gene. The pseudo-reference sample was computed as themedian expression level across all samples for that gene.
The formula to calculate the i-th sample’s scaling factor:
scalei =medianj = 1.n

Eij
mediani = 1.mðEijÞ

where E indicates the expression profile, which hasm samples and n genes. The denominator of the formula can be interpreted as j-th
gene expression level of the pseudo-reference sample.
Characterization of the lncRNA Landscape
We used a strategy similar as described in TCGA Glioblastoma project (Brennan et al., 2013) to characterize the epigenetic lncRNA
landscape in each cancer type, which has successfully generated a patient-centric matrix for PCGs in glioblastoma using an Infinium
HumanMethylation27 microarray. We adapted the strategy to accommodate for the lncRNA genes and the HumanMethylation450
microarray. Specifically, we first identified lncRNA and HM450 probe pairs in which the probe located at the lncRNA’s promoter
region as described previously. Then Spearman correlation coefficients (Rho) between the methylation alteration and gene expres-
sion for each lncRNA and probe pair were calculated for each cancer type. The probe with highest coefficient was selected for the
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procedure reduced the number of CpG probes from N:1 to 1:1. Next, we assigned discrete categories based on the Spearman cor-
relation coefficient according to the following criteria:
1. Strongly negatively correlated (SNC) when the rho value was less than -0.5;
2. Weakly negatively correlated (WNC) when the rho value was between -0.5 and -0.25;
3. No negative correlation (NNC) when the rho value was greater than -0.25.
Next, we assigned samples to either the 30th (T30 or N30) or 70th (T70 or N70) percentile based on the observed beta value across
tumor (T) and normal (N) samples. For a cancer typewith less than 30 normal samples, we randomly selected 24 normal samples from
each of the three different normal tissues (72 samples in total). The three different normal tissues selected for this analysis were gener-
ated by TCGA for breast (BRCA), kidney (KIRC) and lung (LUSC) tumor studies. We finally scored each lncRNA gene per cancer type
per tissue type (tumor and normal) according to the following rules:
1.If percentile 70 < 0.25, we score it as CUN or CUT (constitutively unmethylated in normal or tumor tissue);
2.If percentile 20 > 0.75, we score it as CMN or CMT (constitutively methylated in normal or tumor tissue);
3.If percentile 20 > 0.25 and percentile 70 < 0.75, we score it as IMN or IMT (intermediately methylated in normal or tumor tissue);
4.If it did not fall into any of the above categories, it was scored VMN or VMT (variably methylated in normal or tumor tissue).
Next, we assigned a ‘call’ and a confidence ‘score’ for each of the possible combinations (48) [3 (SNC,WNC, NNC) x 4 (CUN, CMN,
VMN, IMN) x 4 (CUT, CMT, VMT, IMT)] per platform, as shown in Table S5. The methylation calls are as follows:
EA: Epigenetically activated
ES: Epigenetically silenced
UC: No Change
Methylation class confidence scores varied from EAH (epigenetic activation with high confidence), EAL (epigenetic activation with
low confidence), NC (no change), ESL (epigenetic silencing with low confidence) and ESH (epigenetic silencing with high confidence)
here. In this way, we generated aMethylation Patient-Centric Table of DNAmethylation calls for each sample per lncRNA in 20 cancer
types, and calculated the percentage of four types’ methylation status for each lncRNA in each cancer type.
The lncRNAs were ranked by summarized weighted alteration percentages among all the cancer types. Specifically, we give the
EAH percentage with weight 2, EAL percentage with weight 1, UC percentage with weight 0, ESL percentage with weight -1, and ESH
percentage with weight -2. The summarized weighted percentages of each lncRNA was used as a rank score. Generally, lncRNAs
with consistent EA status in multiple cancer types would get a higher score, and the lncRNAs with consistent ES status in multiple
cancer types would show a lower score.
Gene Set Enrichment Analysis (GSEA)
To interpret the function of regulated genes after EPIC1 siRNA treatment, GSEA (version 2.2.0) (Subramanian et al., 2005) was per-
formed using the 50 cancer hallmark gene sets and a gene log2-fold change. To identify the pathways that are correlated with EPIC1
expression in tumor samples, we performed a similar GSEA for each cancer type in TCGA dataset. In this analysis, GSEA was per-
formed on the ranked PCG list based on the Spearmen’s correlation coefficient with EPIC1 expression.
RNA-seq Data Analysis
We developed a STAR-RSEM pipeline, which was revised from the ENCODE RNA-seq analysis pipeline. We used this pipeline to
profile TCGA breast cancer and CCLE breast cancer cell line RNA-seq data, and the RNA-seq data of MCF-7 cells after EPIC1
knockdown. To transfer the bam file to fastq, we used Picard-tools SamToFastq module. FastQC was used to check the sequencing
quality. The RNA-seq data can be downloaded from GEO (GSE98538).
Association Analysis between lncRNA Epigenetic Landscape and Protein-Coding Gene Alteration
Somatic mutations and copy number alterations in 32 cancer types were obtained from TCGA Pan-Cancer project (http://
cancergenome.nih.gov/tcga/). The somatic mutations were identified via the MC3 algorithm. The copy number alterations were
called using the GISTIC algorithm. An alteration profile of 32 cancer types was constructed. The columns of the alteration profile
represent the samples, and the rows represent the tumor genes. If a gene was detected with alterations (non-synonymous somatic
mutation or SCNA) in a sample, we set the profile to 1. Otherwise, the profile was set to 0.
For each PCG-lncRNA pair (denoted asGi and Li), we calculated the probability P(Gi, Li) of observing at least the number of samples
that simultaneously contain alterations in both G1 and Li at random according to Equation 1:
PðG1 ;LiÞ = 1
Xa1
k = 0

a+b
k

c+d
a+ c k


n
a+ c
 (Equation 1)
where n is the total number of samples, a is the number of samples with alterations in both genes, b is the number of samples with
alterations only inG1, c is the number of samples with alterations only in Li, and d is the number of samples without alterations in eithere6 Cancer Cell 33, 706–720.e1–e9, April 9, 2018
gene. The ‘‘hypergeometric test’’ p value was subjected to a Benjamini and Hochberg correction for multiple tests, and gene pairs
with a FDR less than 0.05 were included in the following analysis.
Statistical and Clustering Analysis
Student’s t-test, analysis of variance, chi-square, Wilcoxon rank-sum test, Fisher’s exact test, Kaplan-Meier estimate, and Mantel-
Cox survival analyses were performed using R 2.10.0. Significance was defined as p < 0.05. Benjamini-Hochberg multiple testing
correction (Benjamini and Hochberg, 1995) was used to estimate the FDR when multiple testing correction was applied.
Integrating ChIP-Seq and RNA-Seq Data to Identify and Validate EPIC1-MYC Axis Target Gene
The genome-wide MYC protein binding sites were identified by applying Cistrome algorithm (Mei et al., 2017) on two biological rep-
licates of MYC ChIP-seq assays of MCF-7 cells (Lee et al., 2012). We identified MYC targets that regulated by EPIC1 based on two
criteria: (1) at least one MYC binding peak falls within the TSS-proximal region (from 3 kb upstream to 500 bp downstream) of the
gene; and (2) the gene is differentially expressed between the siEPIC1 and control MCF-7 cells. The top targets of EPIC1-MYC
axis were selected based on their significance of MYC binding signal, differential expression after EPIC1 knockdown, and their roles
in cell proliferation/cycle. For each target, primers were designed to target the MYC binding region, and detailed primer sequences
are listed in Table S5. ChIP-qPCR was further performed to demonstrate whether EPIC1 knockdown decreases the recruitment of
MYC to its target promoter sites.
Antibodies
The following antibodies were used for immunoblotting: rabbit anti-SNRP70 (Abcam, #ab83306), rabbit anti-GAPDH (Santa Cruz,
#sc-25778), rabbit anti-MYC (Cell Signaling, #13987), rabbit anti-p21 (Cell Signaling, #2947), rabbit anti-CDC20 (Cell Signaling,
#14866), rabbit anti-FLAG (Cell Signaling, #14793), rabbit anti-CDC45 (Cell Signaling, #11881), rabbit anti-MAX (Novus, #NBP1-
49963), mouse anti-Cyclin A2 (Santa Cruz, #sc-596), and mouse anti-b-actin (Sigma, #A5441). The following antibodies were
used for co-immunoprecipitation (Co-IP), RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) analysis: rabbit
anti-MYC (Santa Cruz, #sc-789), rabbit anti-MAX (Santa Cruz, #sc-764), rabbit anti-MYC (Cell Signaling, #9402), and normal rabbit
IgG (Cell Signaling, #2729) as a negative control, and anti-FLAG M2 affinity gel (Sigma, #A2220).
Cell Fractionation, Cytoplasmic/Nuclear RNA Isolation
MCF-7, Hs578T, and T-47D cells were subjected to cytoplasmic and nuclear fractionation using a PARISTM kit (ThermoFisher,
#AM1921), and total RNA was isolated from each fraction following the recommended protocol.
RNA Isolation and Quantitative Real-Time PCR (qRT-PCR) Assays
Total RNA was isolated from cultured cells using an RNeasy Mini kit (Qiagen, #74104) according to the manufacturer’s instructions.
cDNAs were synthesized from 0.5 mg of total RNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
#4368813). Real-time PCR was performed with Power SYBR Green PCR Master Mix (Applied Biosystems, #4367659) on a
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Relative gene expression was determined by DDCt normalized
to GAPDH. The primers used are listed in Table S5.
EPIC1 RNA Copy Number Analysis
Total RNA was isolated from 1 x 106 cells using an RNeasy Mini kit. The full-length of EPIC1 RNA was in vitro transcribed with Ribo-
nucleotide solution set (NEB, #N0450) and T7 RNA polymerase (Roche, #10881775001) using the PCR products as a template,
treated with RNase-free DNase I (Promega, #M198A), and then isolated with the RNeasy Mini kit. cDNA was synthesized using
1mg of the total RNA or full-length of EPIC1 RNA. Serial ten-fold dilutions (102 to 109 molecules per ml) of cDNA from in vitro-tran-
scribed EPIC1 RNA were used as a reference molecule for the standard curve calculation. Real-time PCR was performed as above.
Cloning, shRNA Construction, and Lentiviral Transduction
Full-length of EPIC1 was identified and amplified from total RNAs of MCF-7 / T-47D cells by 5’RACE and 3’-RACE using FirstChoice
RLM-RACE Kit (ThermoFisher, #AM1700). To construct retroviral EPIC1 expression plasmids, PCR products containing the CMV-
zsGreen1 portion of pLncEXP (Addgene plasmid # 64865) were inserted into a pBABE puro vector (Addgene, #1764), and the
resulting construct was named as pBABE-lnc. Then full-length and truncated mutants of EPIC1 were cloned into pBABE-lnc with
AgeI andXhoI enzymes or cloned into pCDH-CMV-MCS-EF1-Puro (SystemBiosciences, #CD510B-1) with XbaI andEcoRI enzymes.
Full-length of Flag-tagged or HA-tagged MYC expression vectors were generated using a human MYC cDNA Clone (OriGene,
#SC112715) as a DNA template. Full-length of HA-tagged MAX expression vector was generated using cDNA from MCF-7 cells
as a template. The truncated or deletion mutants and LNA-resistant EPIC1 expression vectors were constructed by using
QuickChange II XL Site-Direct Mutagenesis Kit (Agilent Technologies, #200522). All constructs were confirmed by DNA sequencing
at Genomics Research Core, University of Pittsburgh.
To construct stable EPIC1-expressing cells, pBABE-lnc and lnc-EPIC1 plasmids were transfected into Phoenix cells to produce
retrovirus, and viruses were collected 48 hr post-transfection. MCF-7 cells were infected for 24 hr with the retroviruses and selected
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EPIC1 knockdown constructs were cloned by inserting oligos into a pLKO.1 TRC cloning vector (Addgene, #10878). The oligo se-
quences are listed in Table S5. To produce lentiviral particles, HEK 293T cells were seeded into one 6-cm Petri dish in DMEM with
10% FBS without antibiotics and incubated overnight to reach approximately 80% confluence before transfection. Transfection was
performed using Lipofectamine 2000 Transfection Reagent according to the recommended protocol. Then, 3 mg of pLKO.1 shControl
(shCtrl) or pLKO.1 shEPIC1 plasmid, 2.25 mg of psPAX2 (Addgene, #12260), and 0.75 mg of pVSV-G (Addgene, #8454) were used for
each 6-cm petri dish. After transfection for 6 hr, the medium was changed with fresh DMEM containing 10% FBS, and the cells were
incubated for another 48 hr. Culture medium containing the lentiviral particles was collected and filtered through a 0.45 mm filter to
remove any remaining cells and debris. Target cells were infected for 24 hr with lentiviral particles in the presence of 8 mg/ml
polybrene and screened with puromycin to establish stable cells.
Promoter Cloning and Reporter Assay
Using genomic DNA fromMCF-7 cells as DNA templates, the promoter region ofCCNA2 ranging from -443 bp to +334 bpwas ampli-
fied by PCR and inserted to pGL3 Basic vector (Promega, #E1751) with NheI and HindIII enzymes, named as CCNA2-Luc, and the
promoter region of EPIC1 ranging from -133 bp to +587 bp were inserted to pGL3 Basic vector with HindIII enzymes, named as
EPIC1-Luc. WWP-Luc (p21/WAF1 promoter) was a gift from Bert Vogelstein (Addgene plasmid #16451). For plasmid methylation
followed by the previous report (DiNardo et al., 2001), briefly, 20 mg of EPIC1-Luc were methylated using Methyltransferase
(M. SssI, NEB, #M0226S) at 37C for 12 hr, followed by subsequent inactivation of enzyme at 60C for 20 min. Mock-methylated
mixtures were also performed in the absence of the methylase and S-adenosyl methionine. The methylated and mock-methylated
mixtures were purified using
QIAprep Spin Miniprep Kit (Qiagen, #27106) and the methylation status of the constructs was determined by HpaII digestion and
2% agarose gel eletrophoresis.
Cells were transiently transfected with un-methylated or methylated EPIC1-Luc reporter or a combination of either EPIC1 siRNA,
MYC siRNA, or a negative control siRNAwith CCNA2-Luc or WWP-Luc constructs using LipofectamineTM 2000, and b-Gal was used
as an internal control. After 48 hr, the luciferase and b-Gal activities were detected as described (Niu et al., 2017) in a Wallac 1420
Victor2 Microplate Reader (Perkin Elmer). The luciferase activities were normalized to the b-Gal activities. Data were shown as fold
change over the control group.
Cell Proliferation and Cell Cycle Assay
Cells were seeded at 2,000 cells per well in 96-well culture plates, and MTT assays were performed with a CellTiter 96 Non-Radio-
active Cell Proliferation Assay Kit (Promega, #G4100) following the manufacturer’s guidelines. The absorbance value was measured
at 570 nm using an xMark Microplate Spectrophotometer (Bio-Rad) with a reference wavelength of 630 nm.
For the cell cycle assay, cells were collected, rinsed with PBS, and fixed for a minimum of 2 hr by adding 70% ice-cold ethanol
at -20C. Cells were then sequentially washed once in PBS and BD Pharmingen stain buffer (BD Biosciences, #554656). Cell pellets
were resuspended in 0.5ml of BD Pharmingen PI/RNase staining buffer (BD Biosciences, #550825) and incubated for 15min at room
temperature (RT), and cells were immediately analyzed using an LSRFORTESSA X-20 flow cytometer (BD Biosciences). The data
were analyzed with FlowJo software.
Soft Agar Colony Formation Assay
For each well, 2 ml of 0.6% NuSieve GTG agarose (Lonza, #50081) in culture medium was plated into 6-well plates as the bottom
layer, and the agarose was allowed to solidify at RT. Then, 1 ml of cell mixture containing 104 cells in culture medium and a final con-
centration of 0.35% agarose was carefully plated on top of the bottom layer. The plates were incubated at 37C and 5% CO2 until
colonies were formed, and cells were fed with 0.5 ml of cell culture medium every other week. After 2-3 weeks, colonies were stained
using 0.005% crystal violet in 4% paraformaldehyde solution and counted.
RNA Immunoprecipitation (RIP)
RIP was performed as previously described with minor modifications (Tsai et al., 2010). Briefly, cultured cells were collected by tryp-
sinization, washed once with cold PBS, and then treated with 0.3% formaldehyde in PBS for 10 min at 37C. Then, 1.25 M glycine
dissolved in PBSwas added to a final concentration of 0.125M, and themixture continued to incubate for 5min at RT. The cells were
subsequently washed twice with cold PBS, and the pellets were resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mMNaCl,
1 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 0.5 mM DTT, 1 mM PMSF, and 1 x protease inhibitor cocktail
(Sigma, #P8340)) and incubated on ice for 30minwith shaking. The cleared lysateswere incubated for 4 h at 4Cwith the correspond-
ing antibodies. Pellets were washed twice in RIPA buffer, four times in 1 M RIPA buffer (50 mM Tris-HCl, pH 7.4, 1 M NaCl, 1 mM
EDTA, 0.1% SDS, 1% NP-40, and 0.5% sodium deoxycholate), and then twice in RIPA buffer. The pellets were resuspended and
treated with RIPA buffer containing proteinase K at 45C for 45 min. Finally, RNA was isolated with TRIzol reagent.
RNA Pull-Down Assay
Biotin-labeled full-length and truncated fragments of EPIC1 RNA were transcribed in vitrowith a Biotin RNA Labeling Mix Kit (Roche,
#11685597910) and T7 RNA polymerase (Roche, #10881775001) using the PCR products as a template, treated with RNase-free
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(10 mM Tris-HCl pH 7.0, 0.1 M KCl, 10 mMMgCl2) at 90
C for 2 min, immediately put on ice for another 2 min, and then transferred to
RT for 20 min to allow proper RNA secondary structure formation.
Cells were collected by trypsinization and washed twice with sterilized PBS. Cell pellets were resuspended in 2 ml of pre-chilled
PBS, 2 ml of nuclear isolation buffer (1.28 M sucrose, 40 mM Tris-HCl pH 7.5, 20 mMMgCl2, and 4% Triton X-100) and 6 ml of ster-
ilized DEPC-treated water and incubated on ice for 20 min with frequent vortexing. Nuclei were pelleted by centrifugation at 2,500 g
for 15min, washed once with 1ml of nuclear isolation buffer, resuspended in RIP buffer (150mMKCl, 25mMTris-HCl pH 7.4, 0.5mM
DTT, 0.5% NP-40, 1 mM PMSF, 1 x Superase-in, and 1 x protease inhibitor cocktail), and sheared on ice using a Dounce homoge-
nizer with 15 to 20 strokes. After 1mg of the cleared lysate wasmixed with folded RNA in RIP buffer and incubated for 1 hr at RT, 60 ml
of Dynabeads MyOne Streptavidin C1 magnetic beads (ThermoFisher, #65001) was added to each reaction, and the mixture was
incubated for another 1 hr at RT. Beads were washed five times and boiled in 1 x SDS loading buffer, and the retrieved protein
was analyzed using western blotting.
The in vitro binding assay of biotin-labeled EPIC1 RNA andMYC protein was performed as previously described (Tsai et al., 2010).
Briefly, 0.1 mg of biotinylated RNAwas incubatedwith different amounts of recombinant humanMYCprotein (Abcam, #ab84132) for 1
hr at RT in 200 ml of binding buffer (50mMTris-HCl pH 7.9, 10%glycerol, 100mMKCl, 5mMMgCl2, 10mM b-ME, 0.1%NP-40, 1mM
PMSF, 1 x Superase-in, and 1 x protease inhibitor cocktail). Then, 30 ml of washed streptavidin-conjugated magnetic beads were
added to each reaction, and the mixtures were incubated at RT for 30 min. Beads were washed five times and boiled in 1 x SDS
loading buffer, and the retrieved protein was analyzed using western blotting.
Chromatin Immunoprecipitation (ChIP)
The ChIP assay was performed as previously described (Nelson et al., 2006). Briefly, 1 x 107 cells were cross-linked with a final con-
centration of 1.42% formaldehyde in growth medium for 15 min at RT, and cross-linking was quenched by the addition of glycine to a
final concentration of 125mMand incubation for 5min at RT. Cells were rinsed twice with cold PBS, harvested in IP buffer (50mMpH
7.5 Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, and 1% Triton X-100) supplemented with 1 mM PMSF and 1 x protease
inhibitor cocktail and sonicated to shear the chromatin to yield DNA fragment sizes of 0.5 to 1 kb. Samples were cleared by centri-
fuging at 12,000 g for 10 min at 4C and preincubated for 1 hr with 40 ml of protein A/G agarose beads. A portion of the precleared
samples was used as input DNA. Then, approximately 2 mg of MYC antibody or rabbit normal immunoglobulin (IgG) was added to the
remainder of the samples and incubated for 1 hr at 4C, 40 ml of protein A/G agarose beads (ThermoFisher, #20421) were added, and
the mixture was incubated for 4 hr at 4C. Beads were washed six times with cold IP buffer, and DNA was isolated with 10% Chelex
following the suggested protocol; the total input DNA was also isolated. Quantification was performed using real-time PCR with
SYBR Green Master Mix. Control IgG and input DNA signal values were used to normalize the values from the MYC ChIP to target
genes. The primers for target genes and the negative control are listed in Table S5.
Co-Immunoprecipitation (Co-IP), Protein Isolation and Western Blotting
Co-IP was performed as following, briefly, cells were collected and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mMNaCl, 1 mM
EDT, 1% Triton X-100, PMSF freshly added to a final concentration of 1mM, and 1x protease inhibitor cocktail). After quantification
using a BCA protein assay kit (ThermoFisher, #23225), 1 mg of total protein were used for Co-IP and incubated for overnight with 2 mg
of anti-MYC, anti-MAX antibodies, and normal rabbit IgG as a negative IP control, respectively. The mixtures were incubated for
another 2-4 hr with protein A/G agarose beads, and then beads were washed at least 4 times, and treated and boiled for 10 min
with 1x SDS sample buffer (Bio-Rad, #161-0737).
Cell lysates were also treated with equal volume of 2x SDS sample buffer and resolved by SDS-PAGE under denaturing conditions
and transferred onto PVDF membranes (Bio-Rad, #162-0177). The membranes were blocked with 5% non-fat milk (LabScientific,
#M0841) in 1x PBST at RT for 2 hr and incubated with primary antibody overnight at 4C, followed by incubation with horseradish
peroxidase-conjugated secondary antibodies for 1 hr at RT. Specific bands were visualized with enhanced chemiluminescence
(ECL) substrate (ThermoFisher, #32106) and exposed onto films with an AX 700LE film processor (ALPHATEK).
DATA AND SOFTWARE AVAILABILITY
The RNA-seq datasets for gene expression in MCF-7 cells after siRNA-mediated knockdown of EPIC1 (accession no. GSE98538),
DNA methylation datasets of breast cancer cells (accession no. GSE57342 and GSE44837), and gene expression profile of breast
cancer patients (accession no. GSE20711, GSE21653, GSE17907, GSE20685, GSE16446, and GSE19615), are available at
GEO: https://www.ncbi.nlm.nih.gov/geo/.Cancer Cell 33, 706–720.e1–e9, April 9, 2018 e9
